Salk Institute Study Shows THC May Remove Alzheimer's Plaque-Forming Proteins from Brain Cells
Key Takeaways
- ▸THC and cannabinoids reduce amyloid beta protein levels in laboratory-grown human neurons and eliminate associated cellular inflammation
- ▸This is the first study to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells
- ▸Brain cells naturally produce endocannabinoids that activate protective receptors, suggesting a biological basis for THC's potential neuroprotective effects
Summary
Preliminary laboratory research conducted by scientists at the Salk Institute has found that tetrahydrocannabinol (THC) and other cannabinoids can promote the removal of amyloid beta, a toxic protein associated with Alzheimer's disease, from human neurons grown in culture. The study, published in Aging and Mechanisms of Disease in June 2016, demonstrated that THC exposure reduced amyloid beta protein levels and eliminated the inflammatory response triggered by the protein accumulation, thereby improving nerve cell survival. This represents the first evidence that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells, offering potential new insights into Alzheimer's disease mechanisms.
Senior researcher David Schubert noted that the findings may help explain the role of inflammation in Alzheimer's disease and could provide clues for developing novel therapeutics. The research revealed that brain cells have receptors that can be activated by endocannabinoids—lipid molecules naturally produced by the body—which are similar in function to THC from marijuana. However, Schubert emphasized that these are exploratory laboratory findings and that any potential therapeutic use of THC-like compounds would require rigorous clinical trials before human application.
- Findings are preliminary and limited to lab studies; clinical trials would be necessary before considering therapeutic applications
